ClinicalTrials.gg
TerminatedNCT01871532LoGoUpdated Aug 11, 2016Results posted

Low-dose Gonal-f® in Ovulation Induction

A Phase 4 interventional study of Gonal-f® in Infertility and Monofollicular Development, sponsored by Merck KGaA, Darmstadt, Germany. Terminated at 10 sites in 2 countries. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2016-08-11.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment

Why this study was terminated
Study was terminated because of delays in sourcing replacement Investigational Medicinal Product for the study due to manufacturing delays.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 37 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing follitropin alfa in Infertility — 3 open to participants now, 4 under way, 1 of them phase 3. follitropin alfa · Infertility.

Enrollment
29th of 30
24 · median 159
Started
2013
the only one that year
Phase 4
13 of 30
1 open now
Registered
14th of 30
by date
Lead sponsor
8 of 30
Merck KGaA, Darmstadt, Germany

Among the 30 studies testing follitropin alfa in Infertility, this one is the 29th largest by enrollment, is the only one that started in 2013, is one of 13 in phase 4, and was the 14th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

3 of the 30 studies testing follitropin alfa in Infertility are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About follitropin alfa

follitropin alfa: first FDA approval 1997 (Gonal-f), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 37 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing follitropin alfa in Infertility, or all of them as a file.
02

Study summary

This is a prospective, multicenter, open-label, comparative and parallel-group study of ovulation induction evaluating tailoring of Recombinant follicle stimulating hormone (FSH) treatment using the Gonal-f® prefilled pen in World Health Organization (WHO) Type 2 anovulatory subjects who have previously failed to conceive with clomifene treatment.

Read the detailed description

Subjects will enter a screening period of up to one month before being randomized at the Baseline Visit, which will occur on Day 1 of the subject's menstrual cycle. Each subject will then receive up to 4 weeks treatment with Gonal-f®. If adequate follicular development (assessed by transvaginal ultrasound) is achieved, the subject will proceed to administration of human chorionic gonadotropin (hCG) within 24-48hrs of last Gonal-f® injection (or according to standard site practice).

Following administration of hCG, subjects will attempt to become pregnant via intercourse or intrauterine insemination. The method of conception will be determined by the subject's requirements and standard practice at the clinic site.

All subjects will be followed up appropriately until confirmation of biochemical pregnancy (hCG + minimum 14 days) and clinical pregnancy (hCG + minimum 42 days, for subjects with positive biochemical pregnancy test).

03

Conditions studied

  • Infertility
  • Monofollicular Development

Keywords

  • Monofollicular Development
  • Gonal-f®
  • Recombinant Follicle Stimulating Hormone
  • Ovarian hyperstimulation syndrome (OHSS)
04

Who can participate

Ages eligible
18 Years to 37 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects eligible for ovulation induction treatment, where monofollicular development is the desired treatment outcome and the dose schedule outlined in the protocol is deemed appropriate
  • Premenopausal female subjects, aged between 18 and 37 years inclusive
  • Subjects desirous of pregnancy/willing to conceive
  • Subjects who are infertile due to chronic anovulation demonstrated by cycle duration of greater than 35 days.
  • Subjects who have been treated with clomifene citrate therapy, according to standard site practice, and have failed to ovulate and/or conceive
  • Subjects with follicle stimulating hormone (FSH) and prolactin (PRL) serum values within the normal range in the early follicular phase
  • Subjects with an overall total antral follicle count greater than 10 (of follicle size greater than or equal to 2 millimeter [mm] and less than 11 mm) (that is, total between both ovaries)
  • Subjects with at least one patent tube, as documented by recent (within 2 years before treatment assignment) hysterosalpingography (HSG) or hysterosalpingo contrast sonography (HyCoSy)
  • Subjects with normal uterine cavity, as documented by recent (within 2 years before treatment assignment) hysteroscopy, HSG or ultrasound scan
  • Subjects with (BMI) greater than 20 and less than or equal to 32 kilogram per square meter (kg/m\^2) (BMI is equal to body weight [kilogram {kg}] divided by Height * Height [square meter {m\^2}])
  • Subjects with negative cervical Papanicolaou (PAP) test conducted according to national guidelines and/or standard site practice
  • Male partners of female subjects with sperm compatible with non-assisted fertilization or availability of donor sperm, as confirmed by the Investigator
  • Subjects who are willing and able to comply with protocol requirements and have provided written,

Exclusion criteria

Exclusion Criteria:

  • Subjects with history of to the medicinal product (IMP) (active substance follitropin alpha, FSH, or to any of the of Gonal-f®) or any other drug used in the trial (that is, Ovitrelle)
  • Subjects with ovarian enlargement or ovarian cyst unrelated to Polycystic Ovary Syndrome (PCOS), and of unknown origin on ultrasound
  • Subjects with evidence of diminished ovarian reserve (cycle length less than 26 days; FSH above the upper limit of local serum FSH values, total antral follicle count [AFC] in both ovaries less than 10)
  • Subjects with uterine pathology/abnormalities, which in the opinion of the Investigator could impair pregnancy evolution
  • Subjects who have undergone three or more previous miscarriages
  • Subjects with any previous extrauterine pregnancy
  • Pregnant or lactating female subjects
  • Subjects with abnormal gynecological bleeding of unknown etiology.
  • Subjects with previous history of severe ovarian hyper stimulation syndrome (OHSS) (after clomifene treatment)
  • Subjects who have evidence of current or previous pelvic inflammatory disease before treatment assignment
  • Subjects with tumors of the hypothalamus and pituitary gland
  • Subjects with ovarian, uterine or mammary carcinoma
  • Subjects treated with clomifene citrate or gonadotropins within 1 month of the screening evaluation
  • Subjects with any medical condition which, in the opinion of the Investigator, would prevent an effective response, such as primary ovarian failure, or malformations of the reproductive organs incompatible with pregnancy
  • Subjects with any medical condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the drug
  • Subjects with any systemic disease (for example, insulin-dependent diabetes) or any to being pregnant and/or carrying a pregnancy to term
  • An active substance abuser
  • Known infection with (HIV), or C virus in the trial subject or her male partner
  • Subjects who are currently participating in another clinical trial
  • Subjects who are unable to give written
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Low Dose Gonal-f® Protocol

    Gonal-f was administered subcutaneously daily at a starting dose of 50 International unit (IU) for Week 1, then dose was gradually increased by 12.5 IU for two weeks, with a final increase of 25 IU, up to maximum dose of 100 IU, until Week 4 for subjects with minimal response. After adequate follicular development was achieved, the subject was administration human chorionic gonadotropin (hCG) within 24-48 hours of last Gonal-f injection as per investigator discretion.

    Drug: Gonal-f®

  • Active comparator
    Standard Low Dose Gonal-f® Protocol

    Gonal-f was administered subcutaneously daily at a starting dose of 50 International Units (IU) for Week 1, then dose was gradually increased by 12.5 IU for two weeks, up to maximum dose of 125 IU, until Week 4 for subjects with minimal response. After adequate follicular development was achieved, the subject was administration human chorionic gonadotropin (hCG) within 24-48 hours of last Gonal-f injection as per investigator discretion.

    Drug: Gonal-f®

Interventions

  • Also known as: Recombinant follicle stimulating hormone (r-FSH)

06

What researchers measure

Primary outcomes

  1. Percentage of Cycles With Monofollicular Development

    The monofollicular development was defined as the number of cycles with monofollicular development only one Follicle Greater Than or Equal (\>= to 17 millimeter (mm) and no other follicles Greater than or equal to 14 mm following up to 4 weeks Gonal-f treatment.

    Time frame: Baseline up to 4 weeks

Secondary outcomes

  1. Percentage of Cycles With Bifollicular Development

    The bifollicular development was defined as the number of cycles with bifollicular development of only two follicles greater than or equal to 17 millimeter.

    Time frame: Baseline up to 4 weeks

  2. Percentage of Cycles With Multifollicular Development

    The multifollicular development was defined as the number of cycles with multifollicular development of three or more follicles greater than or equal to 14 millimeter

    Time frame: Baseline up to 4 weeks

  3. Percentage of Ovulatory Cycles

    Ovulation was defined as a serum progesterone (P4 ) level greater than or equal to 10 nanogram per milliliter (ng/mL) or Clinical Pregnancy. Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It excludes ectopic pregnancy.

    Time frame: Baseline up to 42 days post human chorionic gonadotrophin (hCG) administration

  4. Percentage of Cycles Wherein Human Chorionic Gonadotropin (hCG) Was Not Administered

    Time frame: Baseline up to 4 weeks

  5. Percentage of Cycles Resulting in Clinical Pregnancy

    Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It excludes ectopic pregnancy.

    Time frame: 35-42 days post hCG administration

  6. Number of Multiple Pregnancy

    Multiple pregnancy is a pregnancy where more than one fetus develops simultaneously in the womb. There are two types of twinning-identical and fraternal. Identical twins represent the splitting of a single fertilized zygote (union of two gametes or male/female sex cells that produce a developing fetus) into two separate individuals.

    Time frame: 35-42 days post hCG administration

  7. Number of Fetuses

    Time frame: 35-42 days post hCG administration

  8. Number of Miscarriages After Confirmation of Clinical Pregnancy

    Miscarriages were calculated per clinical pregnancy, and clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or confirmed by clinical signs of pregnancy. It excludes ectopic pregnancy.

    Time frame: 35-42 days post hCG administration

  9. Number of Subjects With Ovarian Hyper Stimulation Syndrome (OHSS)

    OHSS was defined as an exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations, classified as mild, moderate or severe according to the degree of abdominal distention, ovarian enlargement and respiratory, hemodynamic and metabolic complications.

    Time frame: up to 42 days post hCG administration

  10. Duration of Recombinant Follicle Stimulating Hormone (rFSH) Stimulation

    Time frame: Baseline up to 4 weeks

  11. Total Dose of Recombinant Follicle Stimulating Hormone (r-FSH) Administered Per Cycle

    Time frame: Baseline up to 4 weeks

  12. Change From Baseline in Anti-Mullerian Hormone (AMH) Levels at Week 4

    Time frame: Baseline, Week 4

  13. Testosterone Levels

    Time frame: Baseline

  14. Sex Hormone Binding Globulin (SHBG) Levels

    Time frame: Baseline

07

Results

Posted Aug 11, 2016
Limitations and caveats
Study was terminated because of delays in sourcing replacement Investigational Medicinal Product (IMP) for the study due to manufacturing delays hence the outcome measure was not assessed.

Participant flow

Participant flow — Overall Study
MilestoneLow Dose Gonal-fStandard Low Dose Gonal-f
Started1212
Subjects received hcg treatment119
Completed1110
Not completed12
Withdrew: Withdrawal by subject12

Outcome measures

PrimaryPercentage of Cycles With Monofollicular Development

The monofollicular development was defined as the number of cycles with monofollicular development only one Follicle Greater Than or Equal (\>= to 17 millimeter (mm) and no other follicles Greater than or equal to 14 mm following up to 4 weeks Gonal-f treatment.

Time frame:
Baseline up to 4 weeks

No measurements were reported for this outcome.

SecondaryPercentage of Cycles With Bifollicular Development

The bifollicular development was defined as the number of cycles with bifollicular development of only two follicles greater than or equal to 17 millimeter.

Time frame:
Baseline up to 4 weeks

No measurements were reported for this outcome.

SecondaryPercentage of Cycles With Multifollicular Development

The multifollicular development was defined as the number of cycles with multifollicular development of three or more follicles greater than or equal to 14 millimeter

Time frame:
Baseline up to 4 weeks

No measurements were reported for this outcome.

SecondaryPercentage of Ovulatory Cycles

Ovulation was defined as a serum progesterone (P4 ) level greater than or equal to 10 nanogram per milliliter (ng/mL) or Clinical Pregnancy. Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It excludes ectopic pregnancy.

Time frame:
Baseline up to 42 days post human chorionic gonadotrophin (hCG) administration

No measurements were reported for this outcome.

SecondaryPercentage of Cycles Wherein Human Chorionic Gonadotropin (hCG) Was Not Administered
Time frame:
Baseline up to 4 weeks

No measurements were reported for this outcome.

SecondaryPercentage of Cycles Resulting in Clinical Pregnancy

Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It excludes ectopic pregnancy.

Time frame:
35-42 days post hCG administration

No measurements were reported for this outcome.

SecondaryNumber of Multiple Pregnancy

Multiple pregnancy is a pregnancy where more than one fetus develops simultaneously in the womb. There are two types of twinning-identical and fraternal. Identical twins represent the splitting of a single fertilized zygote (union of two gametes or male/female sex cells that produce a developing fetus) into two separate individuals.

Time frame:
35-42 days post hCG administration

No measurements were reported for this outcome.

SecondaryNumber of Fetuses
Time frame:
35-42 days post hCG administration

No measurements were reported for this outcome.

SecondaryNumber of Miscarriages After Confirmation of Clinical Pregnancy

Miscarriages were calculated per clinical pregnancy, and clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or confirmed by clinical signs of pregnancy. It excludes ectopic pregnancy.

Time frame:
35-42 days post hCG administration

No measurements were reported for this outcome.

SecondaryNumber of Subjects With Ovarian Hyper Stimulation Syndrome (OHSS)

OHSS was defined as an exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations, classified as mild, moderate or severe according to the degree of abdominal distention, ovarian enlargement and respiratory, hemodynamic and metabolic complications.

Time frame:
up to 42 days post hCG administration
Reported as:
Number · subjects
Number of Subjects With Ovarian Hyper Stimulation Syndrome (OHSS)
subjectsLow Dose Gonal-fStandard Low Dose Gonal-f
Number of Subjects With Ovarian Hyper Stimulation Syndrome (OHSS)00
SecondaryDuration of Recombinant Follicle Stimulating Hormone (rFSH) Stimulation
Time frame:
Baseline up to 4 weeks

No measurements were reported for this outcome.

SecondaryTotal Dose of Recombinant Follicle Stimulating Hormone (r-FSH) Administered Per Cycle
Time frame:
Baseline up to 4 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Anti-Mullerian Hormone (AMH) Levels at Week 4
Time frame:
Baseline, Week 4

No measurements were reported for this outcome.

SecondaryTestosterone Levels
Time frame:
Baseline

No measurements were reported for this outcome.

SecondarySex Hormone Binding Globulin (SHBG) Levels
Time frame:
Baseline

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Dose Gonal-f—0/12 (0%)2/12 (16.7%)
Standard Low Dose Gonal-f—1/12 (8.3%)3/12 (25%)
Most frequent serious events
Most frequent serious events
EventLow Dose Gonal-fStandard Low Dose Gonal-f
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/121/12
Most frequent other events
Most frequent other events
EventLow Dose Gonal-fStandard Low Dose Gonal-f
Abdominal painGastrointestinal disorders0/121/12
Abdominal tendernessGastrointestinal disorders0/121/12
Dry MouthGastrointestinal disorders0/121/12
NauseaGastrointestinal disorders1/120/12
PainGeneral disorders0/121/12
HeadacheNervous system disorders1/120/12
Breast tendernessReproductive system and breast disorders0/121/12
Vaginal dischargeReproductive system and breast disorders0/121/12

Baseline characteristics

Intent-to-Treat (ITT) included all subjects randomized and that had received at least 1 Gonal-f injection and had number of follicles measured at any point.

Age, Continuous
Age, Continuous(years)Low Dose Gonal-fStandard Low Dose Gonal-fTotal
Mean30.8 ± 2.9629.5 ± 3.7530.1 ± 3.37
Sex: Female, Male
Sex: Female, Male(Participants)Low Dose Gonal-fStandard Low Dose Gonal-fTotal
Female121224
Male000
08

Study locations

10 sites
  • Research Site
    Cork, Ireland
  • Research Site
    Dublin, Ireland
  • Research Site
    Galway, Ireland
  • Research Site
    Cambridge, United Kingdom
  • Research site
    Cheshunt, United Kingdom
  • Research Site
    Derby, United Kingdom
  • Research Site
    Edinburgh, United Kingdom
  • Research Site
    Glasgow, United Kingdom
  • Research site
    London, United Kingdom
  • Research Site
    Nottingham, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Mar 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2013
First posted
Jun 6, 2013
Start
Jul 2013
Primary completionActual
Mar 2014
CompletionActual
Nov 2014
Results first posted
Aug 11, 2016
Last update
Aug 11, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01871532
Responsible party
Sponsor
First posted
Jun 6, 2013
Start date
Jul 2013
Primary completion
Mar 2014
Completion
Nov 2014
Results posted
Aug 11, 2016
Last update
Aug 11, 2016

Study contacts

Medical Responsible
study director · Merck Serono Limited, UK

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin alfa

Start the discussion